Strategies to advance translational research into brain barriers

Edward Neuwelt, N. Joan Abbott, Lauren Abrey, William A. Banks, Brian Blakley, Thomas Davis, Britta Engelhardt, Paula Grammas, Maiken Nedergaard, John Nutt, William Pardridge, Gary A. Rosenberg, Quentin Smith, Lester R. Drewes

Research output: Contribution to journalReview articlepeer-review

393 Scopus citations


There is a paucity of therapies for most neurological disorders-from rare lysosomal storage diseases to major public health concerns such as stroke and Alzheimer's disease. Advances in the targeting of drugs to the CNS are essential for the future success of neurotherapeutics; however, the delivery of many potentially therapeutic and diagnostic compounds to specific areas of the brain is restricted by the blood-brain barrier, the blood-CSF barrier, or other specialised CNS barriers. These brain barriers are now recognised as a major obstacle to the treatment of most brain disorders. The challenge to deliver therapies to the CNS is formidable, and the solution will require concerted international efforts among academia, government, and industry. At a recent meeting of expert panels, essential and high-priority recommendations to propel brain barrier research forward in six topical areas were developed and these recommendations are presented here.

Original languageEnglish (US)
Pages (from-to)84-96
Number of pages13
JournalThe Lancet Neurology
Issue number1
StatePublished - Jan 2008

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Strategies to advance translational research into brain barriers'. Together they form a unique fingerprint.

Cite this